Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05112627 · ClinicalTrials.gov registry record
Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 15
- Enrollment target
NCT05112627: Completed study, sponsored by Mayo Clinic.
NCT05112627 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05112627 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
This early phase I trial evaluates blood samples to see if patients undergoing standard of care treatment with either stereotactic body radiation therapy or percutaneous ablation (using radio waves to create heat to destroy the tumor), have an increase in serum immune markers in kidney cancer. Information gained from this study may help doctors make treatment decisions for patients with kidney cancer.
Interventions
- PROCEDURE Biospecimen Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2024-05-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05112627
The ClinicalTrials.gov registry entry for NCT05112627 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT05112627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05112627 about?
NCT05112627 is a clinical study titled "Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy". This early phase I trial evaluates blood samples to see if patients undergoing standard of care treatment with either stereotactic body radiation therapy or percutaneous ablation (using radio waves to create heat to destroy the tumor), have an increase in serum immune markers in kidney cancer. Infor...
What is the current status of trial NCT05112627?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2022-01-24. Estimated completion is 2024-05-15.
What interventions are being tested in trial NCT05112627?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT05112627?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.